Advertisement

Conclusions and Recommendations

  • Michael KaedingEmail author
  • Julia Schmälter
  • Christoph Klika
Open Access
Chapter

Abstract

Pharmacovigilance is vital for public health and patient safety and includes all activities relating to the detection, assessment and prevention of adverse effects due to medicinal products (see WHO 2004). Despite risk assessment before marketing authorisation, all medicines might produce adverse drug reactions (ADRs) during therapeutic use after marketing (Belton and the European Pharmacovigilance Research Group 1997).

Keywords

Member State Healthcare Provider Healthcare Professional General Recommendation Competent Authority 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Belton, K. J. and the European Pharmacovigilance Group (1997). Attitude Survey of Adverse Drug-Reaction Reporting by Health Care Professionals across the European Union. European Journal of Pharmacology 52: 423-427.Google Scholar
  2. Council of Europe (2009). The Ever-Growing Challenge of Medical Liability: National and European Responses. Strasbourg, 2-3 June 2009, Conference Proceedings.Google Scholar
  3. Essinger, K. (2009). Medical Liability: Alternative Ways to Court Procedures. Council of Europe (ed) (2009). The Ever-Growing Challenge of Medical Liability: National and European Responses. Strasbourg, 2-3 June 2009, Conference Proceedings.Google Scholar
  4. Romeo-Casabona, C. (2009). The Legal Approach to Medical Liability – Negligence and Breach of Patient’s Autonomy. Council of Europe (ed) (2009). The Ever-Growing Challenge of Medical Liability: National and European Responses. Strasbourg, 2-3 June 2009, Conference Proceedings.Google Scholar
  5. Simon, J., Jansen, B. (2009). Economic Implications of Medical Liability Claims: Insurance and Compensation Schemes. Council of Europe (ed) (2009). The Ever-Growing Challenge of Medical Liability: National and European Responses. Strasbourg, 2-3 June 2009, Conference Proceedings.Google Scholar
  6. WHO (2004). Pharmacovigilance: Ensuring the Safe Use of Medicines. WHO Policy Perspectives on Medicines 9.Google Scholar

Copyright information

© The Author(s) 2017

Open Access This chapter is licensed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

The images or other third party material in this book are included in the book's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the book's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

Authors and Affiliations

  • Michael Kaeding
    • 1
    Email author
  • Julia Schmälter
    • 1
  • Christoph Klika
    • 1
  1. 1.Institut für PolitikwissenschaftUniversität Duisburg-Essen Institut für PolitikwissenschaftDuisburgGermany

Personalised recommendations